Celladon Corp (NASDAQ:CLDN) on Mar. 4 announced it has completed enrolment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN) stock opened at $12.50 in last session, and closed at $13.54, while the day range of Celladon Corp (NASDAQ:CLDN) stock is $12.21 – $13.91. The stock showed a positive weekly performance of 19.82%.
Small cap biopharmaceutical stock Receptos Inc. (NASDAQ:RCPT) is up 72.4% since the start of this year alone – despite the fact it may not have a drug on the market until 2018 or 2019. Receptos Inc. (NASDAQ:RCPT) stock opened at $49.04 in last session, and closed at $53.10 by gaining 7.12%. The 52 week range of $13.00 – $53.27. Company’s market capitalization is $940.67 million.
C.R. Bard, Inc. (NYSE:BCR) was upgraded by equities research analysts at Ned Davis Research from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, Stock Ratings News reports. C.R. Bard, Inc. (NYSE:BCR) stock increased 0.45% and finished the last session at $146.43. The EPS of the stock remained 8.55. Company’s market capitalization is $11.35 billion.
TG Therapeutics, Inc. (NASDAQ:TGTX), announced it has priced an underwritten sale of 2,702,809 shares of its common stock at $6.71 per share, the closing price on March 11, 2014, to JP Morgan Asset Management’s Global Healthcare Fund. TG Therapeutics, Inc. (NASDAQ:TGTX) stock opened the session at $7.00, and closed the session at $7.40. The 52 week range of the TG Therapeutics, Inc. (NASDAQ:TGTX) stock remained $2.97 – $7.85 and the day range was $7.00 – $7.85.